Abstract
Boosting an effective immune response against established tumors remains a difficult challenge. This study shows the combination of 1) adoptive cell transfer using CD25 depleted splenocytes co-cultured with irradiated tumor cells, and 2) antibody injection therapy using CTLA4 blockade, the elimination of Treg and OX40, which together could eradicate an established MethA tumor in over 50% of the BALB/c mice. Each element of the protocol was shown to be necessary, as elimination of any factor except anti-CD25 antibody injection failed to eradicate the tumor.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use*
-
Antigens, CD / immunology*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
CTLA-4 Antigen
-
Combined Modality Therapy
-
Immunotherapy, Adoptive / methods*
-
Interleukin-2 Receptor alpha Subunit / immunology*
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Neoplasms, Experimental / drug therapy*
-
Neoplasms, Experimental / immunology
-
Receptors, OX40 / immunology*
-
Spleen / cytology
-
Spleen / drug effects
-
Spleen / immunology
-
Treatment Outcome
-
Xenograft Model Antitumor Assays
Substances
-
Antibodies, Monoclonal
-
Antigens, CD
-
Antineoplastic Agents
-
CTLA-4 Antigen
-
Ctla4 protein, mouse
-
Interleukin-2 Receptor alpha Subunit
-
Receptors, OX40
-
Tnfrsf4 protein, mouse